| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Valtteri Kaasinen, Kjell Någren, Tarja Järvenpää, Anne Roivainen, Meixiang Yu, Vesa Oikonen, Timo Kurki, Juha O Rinn. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Journal of clinical psychopharmacology. vol 22. issue 6. 2003-03-31. PMID:12454562. |
donepezil and rivastigmine are acetylcholinesterase (ache) inhibitors used to improve cholinergic neurotransmission and cognitive function in alzheimer's disease (ad). |
2003-03-31 |
2023-08-12 |
human |
| L Parnetti, S Amici, A Lanari, C Romani, C Antognelli, N Andreasen, L Minthon, P Davidsson, H Pottel, K Blennow, V Galla. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 23 Suppl 2. 2003-03-28. PMID:12548360. |
in order to evaluate the biochemical effects of long-term treatment with inhibitors of acetylcholinesterase (ache) in patients with alzheimer's disease (ad), we measured the activities of ache and butyrylcholinesterase (buche) and the concentrations of beta-amyloid (1-42), tau and phosphorylated tau proteins in the cerebrospinal fluid (csf). |
2003-03-28 |
2023-08-12 |
Not clear |
| Ya-Ping Pan, Xiang-Hua Xu, Xiao-Liang Wan. Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons. Neuroscience letters. vol 336. issue 1. 2003-03-14. PMID:12493597. |
galantamine is an acetylcholinesterase inhibitor in alzheimer's disease therapy. |
2003-03-14 |
2023-08-12 |
rat |
| Dawn M Wong, Harry M Greenblatt, Hay Dvir, Paul R Carlier, Yi-Fan Han, Yuan-Ping Pang, Israel Silman, Joel L Sussma. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. Journal of the American Chemical Society. vol 125. issue 2. 2003-03-14. PMID:12517147. |
acetylcholinesterase (ache) inhibitors improve the cognitive abilities of alzheimer patients. |
2003-03-14 |
2023-08-12 |
mouse |
| John V Bowle. Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Stroke. vol 34. issue 2. 2003-03-14. PMID:12574580. |
acetylcholinesterase inhibitors for vascular dementia and alzheimer's disease combined with cerebrovascular disease. |
2003-03-14 |
2023-08-12 |
Not clear |
| Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoo. Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease. International psychogeriatrics. vol 14. issue 2. 2003-02-13. PMID:12243209. |
correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in korean patients with alzheimer's disease. |
2003-02-13 |
2023-08-12 |
human |
| Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoo. Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease. International psychogeriatrics. vol 14. issue 2. 2003-02-13. PMID:12243209. |
the correlates of dropout, efficacy, and adverse events in the treatment of alzheimer's disease (ad) with acetylcholinesterase inhibitors (chei) are unclear. |
2003-02-13 |
2023-08-12 |
human |
| Junji Suwata, Kohzoh Kamata, Tatsushige Nishijima, Tetsuo Yoshikawa, Motoki San. New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient. Nephron. vol 91. issue 2. 2003-02-07. PMID:12053074. |
new acetylcholinesterase inhibitor (donepezil) treatment for alzheimer's disease in a chronic dialysis patient. |
2003-02-07 |
2023-08-12 |
Not clear |
| Junji Suwata, Kohzoh Kamata, Tatsushige Nishijima, Tetsuo Yoshikawa, Motoki San. New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient. Nephron. vol 91. issue 2. 2003-02-07. PMID:12053074. |
the new-generation acetylcholinesterase inhibitor, donepezil, is useful in the treatment of mild-to-moderate alzheimer's disease. |
2003-02-07 |
2023-08-12 |
Not clear |
| L Frölich, T Klinger, F M Berge. Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. Journal of the neurological sciences. vol 203-204. 2003-01-23. PMID:12417372. |
donepezil, a selective acetylcholinesterase inhibitor, is approved for the symptomatic treatment of mild to moderate alzheimer's disease (ad). |
2003-01-23 |
2023-08-12 |
Not clear |
| S Auriacombe, J J Pere, Y Loria-Kanza, B Vella. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Current medical research and opinion. vol 18. issue 3. 2003-01-22. PMID:12094822. |
selective acetylcholinesterase (ache) and dual acetyl- and butyrylcholinesterase inhibitors constitute the only approved agents for the symptomatic treatment of alzheimer's disease (ad). |
2003-01-22 |
2023-08-12 |
Not clear |
| Alison Gree. Biochemical investigations in patients with dementia. Annals of clinical biochemistry. vol 39. issue Pt 3. 2003-01-16. PMID:12038595. |
the recent development of acetylcholinesterase inhibitors to treat patients with alzheimer's disease has increased interest in the use of biochemical markers for the early detection and diagnosis of dementia, but only the measurement of the protein 14-3-3 in cerebrospinal fluid (csf) to help diagnose sporadic creutzfeldt-jakob disease has become accepted clinical practice. |
2003-01-16 |
2023-08-12 |
Not clear |
| Richard B Rosse, Stephen I Deutsc. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clinical neuropharmacology. vol 25. issue 5. 2003-01-13. PMID:12410061. |
galantamine is an inhibitor of acetylcholinesterase and a positive allosteric modulator of nicotinic cholinergic receptors (with a fda-approved indication for the treatment of patients with mild to moderate alzheimer disease (ad) under the trade name reminyl). |
2003-01-13 |
2023-08-12 |
Not clear |
| C Flores-Flores, A Nissim, S Shochat, H Sore. Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library. Journal of neural transmission. Supplementum. issue 62. 2003-01-10. PMID:12456061. |
current alzheimer's disease therapies suppress acetylcholine hydrolysis by inhibiting acetylcholinesterase (ache) at cholinergic synapses. |
2003-01-10 |
2023-08-12 |
human |
| Hiroshi Kogen, Narihiro Toda, Keiko Tago, Shinji Marumoto, Kazuko Takami, Mayuko Ori, Naho Yamada, Kazuo Koyama, Shunji Naruto, Kazumi Abe, Reina Yamazaki, Takao Hara, Atsushi Aoyagi, Yasuyuki Abe, Tsugio Kanek. Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease. Organic letters. vol 4. issue 20. 2002-12-27. PMID:12323018. |
design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for alzheimer's disease. |
2002-12-27 |
2023-08-12 |
Not clear |
| John R Fawcett, Elizabeth Z Bordayo, Kathy Jackson, Howard Liu, Jennifer Peterson, Aleta Svitak, William H Fre. Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain research. vol 950. issue 1-2. 2002-12-23. PMID:12231224. |
inactivation of the machr by the lmw endogenous inhibitor is likely to be a factor in the continual decline of alzheimer's patients, even those taking acetylcholinesterase inhibitors. |
2002-12-23 |
2023-08-12 |
human |
| John R Fawcett, Elizabeth Z Bordayo, Kathy Jackson, Howard Liu, Jennifer Peterson, Aleta Svitak, William H Fre. Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain research. vol 950. issue 1-2. 2002-12-23. PMID:12231224. |
natural antioxidants and pyrophosphate analogs may improve the effectiveness of acetylcholinesterase inhibitors and prove useful in the treatment and prevention of alzheimer's disease since the muscarinic acetylcholine receptor is required for memory, and decreased cholinergic function is a critical deficit in alzheimer's disease. |
2002-12-23 |
2023-08-12 |
human |
| Mathias Zink, Alexander Sartorius, Florian Lederbogen, Fritz A Hen. Electroconvulsive therapy in a patient receiving rivastigmine. The journal of ECT. vol 18. issue 3. 2002-12-20. PMID:12394536. |
we report the case of an 81-year-old woman, suffering from a major depressive episode and incipient alzheimer disease, whom we treated with ect without interrupting therapy with the acetylcholinesterase inhibitor (ache-i) rivastigmine. |
2002-12-20 |
2023-08-12 |
Not clear |
| Matthew G Cottingham, Michael S Hollinshead, David J T Vau. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry. vol 41. issue 46. 2002-12-19. PMID:12427014. |
amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the alzheimer's amyloid-beta peptide. |
2002-12-19 |
2023-08-12 |
human |
| Matthew G Cottingham, Michael S Hollinshead, David J T Vau. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry. vol 41. issue 46. 2002-12-19. PMID:12427014. |
a region near the c-terminus of human acetylcholinesterase (ache) is weakly homologous with the n-terminus of the alzheimer's disease amyloid-beta peptide. |
2002-12-19 |
2023-08-12 |
human |